PROTEIN SENSOR AND MANUFACTURING METHOD THEREOF

專利類型

發明

專利國別 (專利申請國家)

美國

專利申請案號

16/879,790

專利證號

US 11,099,184 B2

專利獲證名稱

PROTEIN SENSOR AND MANUFACTURING METHOD THEREOF

專利所屬機關 (申請機關)

國立臺灣科技大學

獲證日期

2021/08/24

技術說明

本發明是利用大氣電漿技術將親水官能基透過化學反應後，置放於疏水材料表面上，例如金片或是碳/石墨。藉由乾式或是濕式大氣電漿技術，可有效將上述材料的表面親水化，並成功與蛋白質中的氨基酸結合。透過電化學訊號，可以明辨蛋白質種類、數量以及特異性分辨出來，進而提供臨床醫學或是居家照護之功用。研究結果指出，本技術的最低極限偵測度為4.10 pg/mL，並且透過氧氣還原反應(Oxygen reduction reaction, ORR)，鑑定出O-蛋白質醣基化(O-glycosylated)作用進而計算出蛋白質醣化程度。本技術已經經由臨床驗證，並成功應用於多達20組以上的檢體，鑑定成功度達100%。 Patients with ovarian cancer have no clear symptoms. Ovarian cancer can be detected early only through internal diagnosis, ultrasound, and a carcinoma antigen 125 (CA125) tumor index test. More than 60% of patients have advanced ovarian cancer at diagnosis. The traditional chemical fluorescence immunoassay is used to measure CA125 levels; the lowest detection limit is only 35 U mL−1, and it is not good enough in demonstrating early symptoms. Endometriosis, pelvic cavity inflammation, and other gynecological diseases may also increase CA125 levels. Therefore, a method for extracting CA125 information into valuable data for diagnosing ovarian cancer is urgently required; this information could include the glycosylated state of CA125. This study develops a new ultrasensitive electrochemical immunosensor that is composed of reduced graphene oxide (rGO), gold nanoparticles, thionine chloride, bovine serum albumin, and two antibodies. Through hydrogen peroxide reduction, the sensor can detect glycosylated CA125 from ovarian cancer cells and human blood serum by using differential pulse voltammetry. O2 reacts with H+ that formed from altered glycan core structures and produces a strong signal for detecting malignancy. The lowest detection limit of the sensor is 4.10 pg mL−1 (127 nU mL−1), and hence can be used for early ovarian cancer detection. Furthermore, clinical tests (including healthy and patients) demonstrate that the immunosensor has high selectivity and a high regression curve rate of human blood serum analysis can clearly distinguish ovarian cancer and other gynecological diseases. This is the first time that an electrochemical immunosensor has been employed to define and identify ovarian cancer through highly specific and accurate detection.

備註

連絡單位 (專責單位/部門名稱)

技術移轉中心

連絡電話

02-2733-3141#7346

網址